Streetbeat News

Products Services

ATRA

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares dropped after the company announced that its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS) did not meet the primary endpoint. The company is reviewing the data and plans to reduce expenses on ATA188, focusing more on its allogeneic CAR-T pipeline and the expanded tab-cel partnership with Pierre Fabre. This strategy is expected to extend the cash runway beyond Q3 of 2025.

Portfolio Pulse from Nabaparna Bhattacharya

November 09, 2023 | 1:09 pm

MYNZ

Mainz Biomed has partnered with Liquid Biosciences to extend the use of EMERGE in its product development pipeline. This includes analysis of its eAArly DETECT study and the forthcoming U.S. pivotal FDA PMA trial (ReconAAsense). If successful, this will allow Mainz Biomed to advance its current test's capabilities and commercialize a next-generation colorectal cancer screening tool. The eAArly DETECT clinical trial is enrolling 265 subjects across 22 sites and is expected to report results in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:07 pm

IMMP

Immutep has completed enrollment in its TACTI-003 Phase IIb trial of Efti and KEYTRUDA for first line metastatic or recurrent head and neck squamous cell carcinoma. The trial is a significant step in the development of these drugs.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 1:02 pm

ZVSA

ZyVersa Therapeutics has published an article in a peer-reviewed biomedical journal demonstrating that NLRP3 inflammasome inhibition can reduce symptoms of inflammatory bowel disease in an animal model.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:59 pm

PYR

PyroGenesis has announced successful third-party validation of its fumed silica from lab-scale production. This validation could potentially lead to commercial-scale production.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:45 pm

GOOGL

XMTR

Xometry has announced a contract with Google Cloud to leverage Vertex AI to accelerate the deployment of new auto-quote methods and models.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:38 pm

PHIO

Phio Pharmaceuticals has announced the enrollment of the first US patient in a Phase 1B clinical trial for intratumoral PH-762 Anti-PD-1 therapy for the treatment of skin carcinomas. This marks a significant step in the company's clinical development program.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:33 pm

LILM

Lilium has entered into a partnership with Michelin for the development and serial production of tires for the Lilium Jet. The partnership aims to create custom, sustainable, and high-performance tires for the electric vertical take-off and landing (eVTOL) aircraft.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:33 pm

IKNA

Ikena Oncology has shared initial data from the ongoing dose escalation portion of its Phase 1 trial of IK-930. The data shows signs of clinical activity and tumor shrinkage in multiple patients with difficult-to-treat Epithelioid Hemangioendothelioma.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:31 pm

FCDI

IPSC

Century Therapeutics and Fujifilm Cellular Dynamics have announced a new worldwide license deal and expansion of existing licenses for the development and commercialization of cell therapies for the treatment of autoimmune and inflammatory diseases.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 12:23 pm